Back to results
US 2021/0277115 A1Published application
Targeted therapy for small cell lung cancer
OwnerKipp Andrew Weiskopf, Julien Sage +1inventors
InventorsKipp Andrew Weiskopf, Julien Sage, Irving L. Weissman
Life of this patent
Estimating the term…
Abstract
Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRPα.
Claims18
1-7. (canceled)
A method of treating an individual with lung cancer, the method comprising:
- administering to a human subject in need thereof a combination of (i) an agent that selectively blocks CD47 binding to SIRPα and (ii) a targeted therapeutic agent that specifically binds to one or more cell-surface antigens on lung cancer cells, in a dose effective to increase depletion of the lung cancer cells.
A method for the treatment of a lung cancer in a patient, the method comprising:
- administering to said patient an effective dose of a targeted therapeutic agent that specifically binds to a cell surface antigen selected from CD99, CD44, EpCam, CD24, CD166, CD56, CD326, CD298, CD29, CD63, CD9, CD164, CD46, CD59, CD57, and CD165.
Dependencies are inferred from the claim text.